Arcturus Therapeutics Ltd Stock Nasdaq
Stocks
IL0011280240
Biotechnology & Medical Research
| Market Cap | 271M 243M 224M 203M 384M 25.38B 395M 2.68B 1.07B 13.6B 1.02B 994M 42.98B | P/E 2026 * |
-3.25x | P/E 2027 * | -2.62x |
|---|---|---|---|---|---|
| Enterprise Value | 111M 99.49M 91.69M 83.27M 158M 10.4B 162M 1.1B 437M 5.57B 416M 408M 17.62B | EV / Sales 2026 * |
3.95x | EV / Sales 2027 * | 8.86x |
| Free-Float |
93.29% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Arcturus Therapeutics Ltd
| 1 day | +2.70% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 54 | 2013-02-28 |
Dennis Mulroy
DFI | Director of Finance/CFO | 71 | 2026-04-30 |
Alan Cohen
CTO | Chief Tech/Sci/R&D Officer | 65 | 2025-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Farrell
CHM | Chairman | 84 | 2018-05-26 |
James Barlow
BRD | Director/Board Member | 67 | 2018-05-26 |
Magda Marquet
BRD | Director/Board Member | 67 | 2018-05-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.70% | +25.44% | - | - | 271M | |
| +0.01% | +11.10% | +60.83% | +70.43% | 68.32B | |
| +0.79% | +6.82% | +14.16% | +89.22% | 60.26B | |
| +0.06% | +0.09% | +19.79% | +97.32% | 55.86B | |
| +1.60% | +19.44% | +28.80% | +112.95% | 48.43B | |
| -1.32% | +4.78% | +29.15% | +40.40% | 45.34B | |
| -3.54% | -0.60% | +207.76% | +879.50% | 41.76B | |
| -3.33% | +6.90% | +22.78% | +48.07% | 34.5B | |
| -1.26% | -1.20% | +84.21% | +56.55% | 33.8B | |
| -1.49% | +1.16% | +47.05% | +0.16% | 25.96B | |
| Average | -0.58% | +5.39% | +57.17% | +154.96% | 46B | |
| Weighted average by Cap. | -0.67% | +5.25% | +53.98% | +152.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.07M 25.17M 23.2M 21.07M 39.87M 2.63B 40.99M 278M 111M 1.41B 105M 103M 4.46B | 30.55M 27.4M 25.25M 22.93M 43.4M 2.86B 44.61M 302M 120M 1.53B 115M 112M 4.85B |
| Net income | -82.5M -73.99M -68.19M -61.92M -117M -7.74B -120M -816M -325M -4.14B -310M -303M -13.1B | -114M -102M -94.08M -85.44M -162M -10.67B -166M -1.13B -449M -5.72B -427M -418M -18.08B |
| Net Debt | -160M -143M -132M -120M -227M -14.97B -233M -1.58B -630M -8.02B -599M -587M -25.36B | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
